Literature DB >> 11513329

Cytochrome P450 in the brain; a review.

E Hedlund1, J A Gustafsson, M Warner.   

Abstract

After many frustrating decades of unsuccessful attempts to characterize the isoforms of P450 in the brain, several scientific breakthroughs in the 80s and 90s have resulted in major advances in our understanding of cytochromes P450 (CYP) in brain. We now know that classical CYP inducers, e.g. phenobarbital and pregnenolone 16alpha-carbonitrile, which regulate drug-metabolizing enzymes in the liver, are specific ligands for ligand-activated transcription factors, and that the brain content of many of these transcription factors is low. This explains why these inducers have little effect on brain CYP content. The most effective inducers of brain P450 are some of the CNS active drugs and solvents. The level of CYPs in brain, approximately 0.5-2% of that in liver, is too low to significantly influence the overall pharmacokinetics of drugs and hormones in the body. Instead CYPs appear to have specific functions in brain, e.g. regulation of the levels of endogenous GABAA receptor agonists maintenance of brain cholesterol homeostasis and elimination of retinoids The novel CYPs which catalyse these reactions have recently been characterized. They are abundantly expressed in the brain confirming what has been previously found, i.e. that the major hepatic, adrenal and gonadal CYP isozymes contribute very little to the overall content of CYP in brain. It is not clear what fraction of brain CYP has been characterized, although a complete characterization of constitutive and induced CYPs in brain is essential for understanding the role of these enzymes in brain physiology as well as in age-related and xenobiotic-induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513329     DOI: 10.2174/1389200013338513

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  29 in total

1.  Neurobehavioral abnormalities in a brain-specific NADPH-cytochrome P450 reductase knockout mouse model.

Authors:  C Fang; V J Bolivar; J Gu; W Yang; S O Zeitlin; X Ding
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

Review 2.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 3.  The High Cost of Stroke and Stroke Cytoprotection Research.

Authors:  Paul A Lapchak; John H Zhang
Journal:  Transl Stroke Res       Date:  2016-12-30       Impact factor: 6.829

Review 4.  Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke.

Authors:  Cameron Rink; Savita Khanna
Journal:  Antioxid Redox Signal       Date:  2010-12-04       Impact factor: 8.401

5.  Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition.

Authors:  Jun Yang; Melissa A VanAlstine; James G Phillips; Mark P Wentland; Lindsay B Hough
Journal:  Acta Pharm Sin B       Date:  2012-04       Impact factor: 11.413

6.  Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice.

Authors:  Helen J Renaud; Julia Yue Cui; Mohammed Khan; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

7.  Controlled iontophoresis coupled with fast-scan cyclic voltammetry/electrophysiology in awake, freely moving animals.

Authors:  Anna M Belle; Catarina Owesson-White; Natalie R Herr; Regina M Carelli; R Mark Wightman
Journal:  ACS Chem Neurosci       Date:  2013-03-26       Impact factor: 4.418

8.  Monocrotophos Induces the Expression of Xenobiotic Metabolizing Cytochrome P450s (CYP2C8 and CYP3A4) and Neurotoxicity in Human Brain Cells.

Authors:  Vinay Kumar Tripathi; Vivek Kumar; Ankita Pandey; Pankhi Vatsa; Anupam Dhasmana; Rajat Pratap Singh; Sri Hari Chandan Appikonda; Inho Hwang; Mohtashim Lohani
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

Review 9.  Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Authors:  Ramón Cacabelos
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 10.  HIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation.

Authors:  Peter S Silverstein; Santosh Kumar; Anil Kumar
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.